• Publications
  • Influence
Sofosbuvir for previously untreated chronic hepatitis C infection.
BACKGROUND In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection. Expand
  • 1,661
  • 94
  • PDF
Telaprevir for retreatment of HCV infection.
BACKGROUND Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin. METHODS In thisExpand
  • 1,571
  • 75
  • PDF
Boceprevir for previously treated chronic HCV genotype 1 infection.
BACKGROUND In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment areExpand
  • 1,635
  • 68
  • PDF
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
BACKGROUND Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, theseExpand
  • 1,207
  • 62
  • PDF
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
BACKGROUND Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferonExpand
  • 1,033
  • 62
  • PDF
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvirExpand
  • 1,082
  • 60
  • PDF
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive
BACKGROUND Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir. METHODS We enrolled patients withExpand
  • 773
  • 56
  • PDF
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitorExpand
  • 1,043
  • 39
  • PDF
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label,
BACKGROUND Peginterferon plus ribavirin achieves sustained virological response (SVR) in fewer than half of patients with genotype 1 chronic hepatitis C virus infection treated for 48 weeks. WeExpand
  • 721
  • 34
  • PDF
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
BACKGROUND Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmetExpand
  • 1,220
  • 33
  • PDF
...
1
2
3
4
5
...